In Trodelvy’s FDA-approved indication of metastatic triple-negative breast cancer (TNBC), the anti-TROP-2 drug cut the risk of disease progression by 59% over chemotherapy in patients who had ...

Trodelvy (sacituzumab govitecan-hziy) is a brand-name drug prescribed for certain breast cancers. It’s given as an intravenous (IV) infusion by a healthcare professional. The dosage can vary ...

Gilead has tagged Trodelvy as a cornerstone of its ambition to have a third of its revenue from oncology by 2030. The TROP2-targeted antibody-drug conjugate was the centerpiece of Gilead’s $21 ...

Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 months vs 7.8 months when Keytruda was given in combination with chemotherapy.

Withhold Trodelvy for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider G-CSF for secondary prophylaxis.

Trodelvy has not been approved by any regulatory agency for the treatment of HR+/HER2- metastatic breast cancer. Its safety and efficacy have not been established for this indication.

Trodelvy has accelerated U.S. approval for treating advanced urothelial cancer, but Gilead on Thursday said a large trial failed to confirm that the drug improved survival.

These findings support the expectation that Trodelvy combined with Keytruda will become the new SOC in PD-L1-positive TNBC, shifting the frontline treatment paradigm from chemoimmunotherapy to ADC ...

Disclaimer - All information and content on this site are provided for informational and educational purposes only. They should NOT be used for the diagnosis or treatment of any health-related ...

“Trodelvy has the potential to become a cornerstone treatment in metastatic urothelial cancer, and we are excited about the expected results from the ongoing Phase 3 TROPiCS-04 study that may ...

Trodelvy (sacituzumab govitecan) demonstrated a relatively high response rate with rapid responses in patients with locally advanced (cancer that has spread beyond its original size) or metastatic ...

An accelerated approval for Gilead Sciences’ cancer drug Trodelvy could be in question after the company disclosed Thursday afternoon that a confirmatory trial failed to meet its main objective ...